cells. Untreated cells (left panels) or exposed to 25 ng/ml EGF (10 min, middle panels) or 1 μM PGE 2 (60 min, right panels) were reconstructed in XY, XZ and YZ axis. EGFR is visualized in green and the nuclei in blue.
Immunoblotting analysis of EGFR expression in cytosolic and nuclear fraction in GLC82 cells exposed for 60 min to 1 µM EP3 agonist. (B) Confocal analysis of EGFR localization in GLC82 treated with EP3 agonist for 60 min. EGFR was stained in green, DAPI (blue) was used to counterstain the nuclei. Confocal pictures were acquired in the middle section of nuclei at 63× magnification. Scale bars, 20 μm. Boxed areas are shown in detail in the inset. 
Supplementary Figure 8: EP3 knockdown does not alter EGF-induced EGFR nuclear translocation. A549 cells
were transfected with siRNA control or siRNAs against EP3 receptor for 24 h. After, cells were starved overnight and treated with 25 ng/ml EGF for 10 min. Cells were stained for EGFR (green) and DAPI (blue). Confocal pictures were acquired in the middle section of nuclei at 63× magnification. Scale bars, 20 μm. Boxed areas are shown in detail in the inset.
Immunoblotting analysis of EGFR localization in A549 exposed for 10 min to 25ng/ml EGF with or without 10 µM PP1 or SU6656. Tubulin and Lamin A were used as loading control for cytosolic and nuclear fraction, respectively. (C) A549 cells were transfected with Vector control or a plasmid bearing constitutive-active SRC (pcSRC-Y527F) for 24 h and 48 h. Immunoblotting analysis of SRC phosphorylated on Tyr 416 in A549 transfected for 24 h or 48 h was performed as control for plasmid expression and SRC activation. Actin was used as loading control (left panel). EGFR expression at 24 h or 48 h in cytosolic and nuclear fraction in A549 transfected with pcSRC-Y527F (right panel).
